TABLE 5.
Sensitivity analysis: cohort characteristics at baseline, subset study population with Medicare Parts A, B, and D
| Category or statistic | Teriparatide cohort(n = 105 794) | Comparator cohort(n = 297 509) |
|---|---|---|
| Sex, n (%) | ||
| Male | 9129 (8.6) | 24 662 (8.3) |
| Female | 96 665 (91.4) | 272 847 (91.7) |
| Age (years) on index date, mean (SD) | 77.3 (7.72) | 77.7 (8.03) |
| Length of look‐back period (months), mean (SD) | 36.9 (28.25) | 35.4 (26.90) |
| Patients from states with participating cancer registries, n (%) | 68 134 (64.4) | 191 002 (64.2) |
| Use of corticosteroid drugs before the index date, n (%) | 40 841 (38.6) | 91 026 (30.6) |
| Use of other osteoporosis drugs before the index date, n (%) | 62 549 (59.1) | 78 652 (26.4) |
| Medications by AHFS therapeutic class within the 4 months before the index date, n (%) | ||
| Antihistamine drugs | 5198 (4.9) | 14 970 (5.0) |
| Anti‐infective agents | 49 827 (47.1) | 145 844 (49.0) |
| Antineoplastic agents | 7683 (7.3) | 15 330 (5.2) |
| Autonomic drugs | 34 267 (32.4) | 88 182 (29.6) |
| Blood derivatives | 0 (0.0) | n < 11 |
| Blood formation, coagulation, and thrombosis agents | 20 481 (19.4) | 65 649 (22.1) |
| Cardiovascular drugs | 78 657 (74.3) | 249 518 (83.9) |
| Central nervous system agents | 77 473 (73.2) | 198 733 (66.8) |
| Diagnostic agents | 114 (0.1) | 1290 (0.4) |
| Electrolytic, caloric, and water balance | 41 015 (38.8) | 155 028 (52.1) |
| Enzymes | 309 (0.3) | 1311 (0.4) |
| Respiratory tract agents | 6302 (6.0) | 14 931 (5.0) |
| Eye, ear, nose, and throat preparations | 27 687 (26.2) | 81 886 (27.5) |
| Gastrointestinal drugs | 52 906 (50.0) | 136 276 (45.8) |
| Gold compounds | n < 11 | n < 11 |
| Heavy‐metal antagonists | 33 (0.0) | 30 (0.0) |
| Hormones and synthetic substitutes | 57 809 (54.6) | 168 155 (56.5) |
| Local anesthetics | 988 (0.9) | 3489 (1.2) |
| Oxytocics | 0 (0.0) | 0 (0.0) |
| Serums, toxoids, and vaccines | 1268 (1.2) | 2576 (0.9) |
| Skin and mucous membrane agents | 29 268 (27.7) | 77 145 (25.9) |
| Smooth muscle relaxants | 9176 (8.7) | 24 579 (8.3) |
| Vitamins | 2335 (2.2) | 4237 (1.4) |
| Miscellaneous therapeutic agents | 36 503 (34.5) | 65 436 (22.0) |
| Unclassified | 0 (0.0) | 0 (0.0) |
| Number of unique AHFS therapeutic classes within the 4 months before the index date, n (%) | ||
| 0‐2 | 8812 (8.3) | 23 209 (7.8) |
| 3‐5 | 20 824 (19.7) | 56 619 (19.0) |
| 6‐8 | 25 592 (24.2) | 71 175 (23.9) |
| 9‐11 | 21 531 (20.4) | 60 925 (20.5) |
| 12‐15 | 17 757 (16.8) | 51 679 (17.4) |
| >15 | 11 278 (10.7) | 33 902 (11.4) |
| Risk factors, n (%) | ||
| Radiation use | 3061 (2.9) | 12 891 (4.3) |
| History of Paget's disease of the bone | 630 (0.6) | 1241 (0.4) |
| Health status proxies | ||
| History of vertebral or hip/pelvic fracture, n (%) | 24 683 (23.3) | 24 162 (8.1) |
| History of cancer, n (%) | 37 356 (35.3) | 101 575 (34.1) |
| Number of inpatient and outpatient visits in the 4 months before the index date | ||
| 0 | 27 467 (26.0) | 106 033 (35.6) |
| 1 | 19 078 (18.0) | 59 619 (20.0) |
| 2 | 14 631 (13.8) | 38 383 (12.9) |
| ≥3 | 44 618 (42.2) | 93 474 (31.4) |
| Charlson comorbidity index | ||
| Mean (SD) | 3.8 (3.25) | 3.8 (3.31) |
Abbreviations: AHFS = American Hospital Formulary Services.
Note: To protect patient privacy, non‐zero cell counts <11 cannot be disclosed for Medicare data.